DEFA14A: Cardiff Oncology Amends By-Laws Amid Stockholder Lawsuit Ahead of Annual Meeting

Cardiff Oncology amended its by-laws to clarify voting standards and address a stockholder lawsuit alleging improper voting procedures.

Summary

• Cardiff Oncology's Board of Directors amended the company's by-laws on May 30, 2024, to clarify that directors are elected by a plurality of votes and other matters require a majority vote.
• This amendment was made in response to a stockholder lawsuit filed on May 13, 2024, alleging that the company's previous by-laws were misinterpreted regarding the treatment of broker non-votes.
• The lawsuit also challenged the validity of the 2022 election of directors Renee Tannenbaum and Mani Mohindru, and the amendment to the 2021 Equity Incentive Plan.
• The Board of Directors believes the lawsuit is without merit but amended the by-laws to confirm voting standards for the 2024 Annual Meeting.
• The company rescinded equity grants made in reliance on the 2022 amendment to the 2021 Equity Incentive Plan and approved replacement grants contingent on stockholder approval of Proposal 3.
• As of June 2, 2024, there were approximately 44,737,191 shares outstanding on a basic basis and 54,123,787 on a fully diluted basis.
• If Proposal 3 is approved, the total number of shares available for issuance under the 2021 Plan will be 8,150,000, representing approximately 18.2% and 13.8% of common stock on a basic and fully-diluted basis, respectively.
• Proxies submitted before the supplement date will be voted as instructed unless a later dated proxy is submitted.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is proactively addressing a lawsuit and clarifying its by-laws, the existence of the lawsuit and the need to rescind equity grants introduce uncertainty.

Positives

• The Board of Directors is taking proactive steps to address the stockholder lawsuit and clarify voting standards.
• The company is seeking stockholder approval for replacement equity grants, ensuring continued alignment of incentives.
• The company believes the stockholder's claims are without merit and intends to oppose the claims in litigation.

Negatives

• A stockholder lawsuit has been filed against the company, alleging improper voting procedures.
• The company had to rescind equity grants made in reliance on a previous amendment to the 2021 Equity Incentive Plan.
• The lawsuit creates uncertainty and could potentially distract management.

Risks

• The outcome of the stockholder lawsuit is uncertain and could have financial and operational implications.
• Failure to obtain stockholder approval for Proposal 3 could impact the company's ability to grant equity incentives.
• The lawsuit could damage the company's reputation and investor confidence.

Future Outlook

The company is seeking stockholder approval for Proposal 3 to approve replacement equity grants and increase the number of shares available under the 2021 Equity Incentive Plan.

Management Comments

• The Board of Directors believes the stockholder's claims are without merit and intends to oppose the claims in litigation.
• The Board of Directors adopted the amendments to the By-Laws to confirm and clarify the applicable voting standards that will apply to the business transacted at the 2024 Annual Meeting.

Industry Context

Companies often face stockholder lawsuits regarding corporate governance matters, particularly concerning voting rights and equity compensation plans. This situation highlights the importance of clear and unambiguous by-laws and proactive communication with stockholders.

Comparison to Industry Standards

• Many companies in the biotechnology sector utilize equity incentive plans to attract and retain talent, with the percentage of shares reserved for such plans typically ranging from 10% to 20% of outstanding shares.
• The lawsuit's focus on voting standards is not uncommon, as institutional investors and activist shareholders often scrutinize corporate governance practices to ensure alignment with shareholder interests.
• Comparable companies like Mirati Therapeutics and Revolution Medicines also have equity incentive plans and face similar governance challenges.

Corporate Governance

Legal Proceedings

• Travis Vana, a purported stockholder of the Company, filed a verified stockholder class action and derivative complaint in the Court of Chancery of the State of Delaware against the Company, and against James Armitage, Mark Erlander, Rodney Markin, Mani Mohindru, Gary Pace, Renee Tannenbaum, Lale White, Tod Smeal, Fairooz Kabbinavar and James Levine.

Stakeholder Impact

• Shareholders: The lawsuit and by-law amendment could impact shareholder value and voting rights.
• Employees: The rescission and replacement of equity grants could affect employee compensation and morale.
• Management: The lawsuit requires management's attention and resources.

Next Steps

• Stockholder vote on Proposal 3 regarding the 2021 Equity Incentive Plan.
• Resolution of the stockholder lawsuit.
• Annual Meeting of Stockholders on June 20, 2024.

Key Dates

Keywords

Cardiff Oncology, By-laws, Stockholder Lawsuit, Voting Standards, Equity Incentive Plan, Annual Meeting, Proxy Statement